SUTRO BIOPHARMA, INC.·4

Sep 22, 5:01 PM ET

Gerber Hans-Peter 4

4 · SUTRO BIOPHARMA, INC. · Filed Sep 22, 2025

Insider Transaction Report

Form 4
Period: 2025-09-18
Gerber Hans-Peter
CHIEF SCIENTIFIC OFFICER
Transactions
  • Exercise/Conversion

    Restricted Stock Units (RSUs)

    2025-09-1837,50075,000 total
    Exp: 2027-09-18Common Stock (37,500 underlying)
  • Exercise/Conversion

    Common Stock

    2025-09-18+37,50068,249 total
  • Tax Payment

    Common Stock

    2025-09-18$0.90/sh13,417$12,07554,832 total
Footnotes (3)
  • [F1]Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person.
  • [F2]Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
  • [F3]The RSU award vests annually as to 1/4th of the total award beginning on September 18, 2024, subject to the reporting person's continued service to the Issuer on each vesting date.

Documents

1 file
  • 4
    form4-09222025_090937.xmlPrimary